Related Experiment Video
Updated: Jul 12, 2025

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
[Cardiovascular calcifications in dialysis patients]
Pablo Ureña Torres1,2, Charles Chazot3
1Chef de service de dialyse de l’AURA Nord, Saint-Ouen ; Hôpital Bichat, 12, rue Anselme, 93400 Saint-Ouen, France
Insights
Cardiovascular calcifications are common in advanced chronic kidney disease and dialysis patients, leading to poor outcomes. Current guidelines for managing this risk are underutilized, necessitating new therapeutic strategies.
Area of Science:
- Nephrology
- Cardiology
- Vascular Biology
Background:
- Patients with advanced chronic kidney disease (CKD) and those on dialysis exhibit a high prevalence of cardiovascular calcifications.
- These calcifications are linked to severe complications and decreased life expectancy in this vulnerable population.
- Existing recommendations and imaging scores aim to detect and manage cardiovascular risk, but their practical application remains limited.
Purpose of the Study:
- To highlight the clinical significance of cardiovascular calcifications in advanced CKD and dialysis patients.
- To emphasize the gap between current recommendations and clinical practice in managing cardiovascular risk.
- To explore emerging and evaluated therapeutic strategies for preventing and treating cardiovascular calcifications.
Main Methods:
- Review of current literature and clinical guidelines on cardiovascular calcifications in CKD and dialysis.
- Analysis of the challenges in applying existing management strategies.
- Identification and summary of novel therapeutic approaches under investigation.
Main Results:
- Cardiovascular calcifications are a major cause of morbidity and mortality in advanced CKD and dialysis patients.
- Despite established guidelines, the management of cardiovascular risk factors and calcifications is inconsistently applied.
- Several new therapeutic agents and strategies, including sodium thiosulfate, rheopheresis, vitamin K, magnesium, and SNF-472, are being evaluated.
Conclusions:
- Effective prevention and treatment of cardiovascular calcifications require addressing traditional atherosclerosis risk factors, mineral and bone disorders, and optimizing dialysis.
- There is a critical need for improved adherence to current guidelines and the development of novel therapies.
- Emerging treatments show promise for mitigating the burden of cardiovascular calcifications in CKD and dialysis populations.
Abstract:
Patients with advanced chronic kidney disease and those already on dialysis have an increased prevalence of cardiovascular calcifications. They are the cause of severe complications and are associated with a reduced life expectancy in these patients. Recommendations and imaging scores have been developed to detect and assess their importance, to guide and improve the management of cardiovascular risk. However, despite these recommendations, current practice teaches us that they are only partially applied. The prevention and treatment of cardiovascular calcifications go through the correction of classic risk factors associated with atherosclerosis, mineral and bone metabolism disorders and by optimizing the dose and the efficiency of dialysis. New therapeutic strategies are beginning to emerge, others are being evaluated, such as sodium thiosulfate, rheopheresis, vitamin K, magnesium supplementation, and SNF-472.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Hemodialysis II: Procedure and Complications
Chronic Kidney Disease IV: Nursing Management
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction

